



Published in final edited form as:

Nat Neurosci. 2015 November ; 18(11): 1556–1558. doi:10.1038/nn.4126.

Modulation of TREM2 by CD33: a protein QTL study integrates Alzheimer loci in human monocytes

Gail Chan^{1,2,3,4}, Charles C. White^{1,2,3}, Phoebe A. Winn^{1,2,3}, Maria Cimpean^{1,2,3}, Joseph M. Replogle^{1,2,3,4}, Laura R. Glick^{1,2,3}, Nicole E. Cuerdon^{1,2,3}, Katie J. Ryan^{1,2,3,4}, Keith A. Johnson^{2,4}, Julie A. Schneider⁵, David A. Bennett⁵, Lori B. Chibnik^{1,2,3,4}, Reisa A. Sperling^{2,4}, Elizabeth M. Bradshaw^{1,2,3,4,*}, and Philip L. De Jager^{1,2,3,4,*}

¹Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA

²Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, MA

³Program in Medical and Population Genetics, Broad Institute, Cambridge, MA

⁴Harvard Medical School, Boston, MA

⁵Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL

Abstract

Here, we report results from a protein quantitative trait analysis in monocytes from 226 individuals to evaluate cross-talk between Alzheimer loci. We find that the *NME8* locus influences *PTK2B* and that the *CD33* risk allele leads to greater TREM2 expression. Further, we observe (1) a decreased TREM1/TREM2 ratio with a *TREM1* risk allele, (2) decreased TREM2 expression with CD33 suppression, and (3) elevated cortical *TREM2* mRNA expression with amyloid pathology.

Genetic association studies of late-onset Alzheimer's disease (AD) have identified several susceptibility variants in loci harboring innate immune-related genes including *CLU*, *CRI*, *CD33*, *EPHA1*, *MS4A4E/MS4A6A*, *PTK2B*, *TREM2* and *TREML2*^{1–6}. In addition, our group has recently uncovered common variants in *TREM1* (rs6910730^G) and *TREM2* (rs7759295^C) that are associated with increased AD pathology and cognitive decline⁷. The role of the innate immune system is further supported by (1) evidence implicating microglia and infiltrating monocytes/macrophages in the accumulation of amyloid pathology^{8–10}, (2) the *TYROBP (DAP12)* microglial transcriptomic network associated with AD¹¹, and (3) our recent work on the Immunological Variation (ImmVar) Project, which revealed that AD-

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

* equal contribution

Author Contributions

G.C., P.L.D. and E.M.B. designed and implemented the study and wrote the manuscript. G.C. planned and conducted the experiments with technical assistance from P.A.W., M.C. and K.J.R. C.C.W., J.M.R., L.B.C. and G.C. performed statistical analyses and assisted with the interpretation of results. P.L.D., L.R.G. and N.E.C. coordinated the collection of blood from PGP. R.A.S. and K.A.J. provided blood samples and genetic data from HABS. J.A.S. and D.A.B. contributed clinical, genetic and post-mortem data from ROS-MAP. P.L.D. coordinated access to all of the cohorts. All authors contributed to the review of the manuscript.

associated loci regulate mRNA expression levels of nearby genes (i.e. are *cis*-expression quantitative trait loci, *cis*-eQTLs) in monocytes but not T cells¹².

How these AD risk loci act to affect innate immune function and AD susceptibility is not yet clear. Large mRNA expression screens, such as the ImmVar Project, have provided a first evaluation of functional consequences¹², but mRNA levels do not necessarily reflect protein levels and cannot identify post-translational effects on protein expression. To address this, we measured expression of TREM1, TREM2, TREML2, TYROBP, PTK2B and CD33 - six proteins expressed in monocytes that have been previously shown to be either (1) the target of an eQTL with an AD variant *in cis* (CD33, TREM1, PTK2B) or (2) important in AD (TREM2, TREML2, and TYROBP) - by flow cytometry in primary human monocytes from 115 younger, healthy subjects of the PhenoGenetic Project (PGP) at Brigham and Women's Hospital as well as 61 older, cognitively non-impaired subjects from the Harvard Aging Brain Study (HABS) (Supplementary Table 1). We first analyzed previously reported *cis*-eQTLs at the protein level (*cis*-pQTLs) and then performed our primary investigation: identifying *trans* effects of 26 single nucleotide polymorphisms (SNPs) robustly associated with AD or AD neuropathology (Supplementary Table 2) on TREM1, TREM2, TREML2, TYROBP, PTK2B, and CD33 protein expression (*trans*-pQTLs). Thus, the scope of our discovery screen to identify novel effects *in trans* was highly targeted. For both *cis* and *trans* evaluations, we meta-analyzed the two datasets in a discovery phase and attempted to validate the most suggestive results ($p < 0.01$ for *trans* associations) in an independent sample of 50 PGP subjects. A joint analysis (discovery + validation) was also performed to summarize all available data for the SNP:protein pairs that were validated. Details of the analysis method, including batch correction and normalization, can be found in the Online Methods Section.

Consistent with ImmVar data¹², CD33, TREM1, TREM2, TREML2 and TYROBP were expressed predominantly by monocytes, while PTK2B was highly expressed by both lymphocytes and monocytes (Supplementary Fig. 1). In monocytes, we found strong positive correlations between the expression of intracellular proteins PTK2B and TYROBP ($t_{175}=5.57$, $p_{\text{joint}}=9.26 \times 10^{-8}$) and cell surface molecules CD33 and TREM2 ($t_{224}=4.55$, $p_{\text{joint}}=8.83 \times 10^{-6}$) (Supplementary Fig. 2).

Evaluating previously reported associations, we noted the strong correlation between the *TREM1* susceptibility allele rs6910730^G and reduced TREM1 surface expression ($z_{\text{joint}}=-4.05$, $p_{\text{joint}}=5.02 \times 10^{-5}$; Table 1 and Fig. 1a), which we recently reported in a subset of the PGP discovery subjects⁷. We also confirmed the robust association of the *CD33* rs3865444^C risk allele with increased CD33 expression¹⁰ ($z_{\text{joint}}=13.6$, $p_{\text{joint}}=3.12 \times 10^{-42}$) and validated the rs28834970-*PTK2B* monocyte *cis*-eQTL¹² at the protein level ($z_{\text{joint}}=3.42$, $p_{\text{joint}}=6.36 \times 10^{-4}$) (Table 1). These results are important in illustrating the properties of our dataset in which known effects of susceptibility loci are clearly observed and help to support the narrative that we have pursued in selecting the target genes in this study.

Having validated these associations, we next evaluated whether multiple *cis*-pQTLs exist within these loci. In the *TREM1* locus, we found that rs2627567^A decreased TREM1 surface expression ($z_{\text{joint}}=-4.96$, $p_{\text{joint}}=6.89 \times 10^{-7}$) independently from rs6910730^G (Table 1 and

Fig. 1b). Curiously, unlike rs6910730, rs2627567 is not associated with AD phenotypes in Religious Orders Study and Memory and Aging Project (ROS-MAP) subjects (Supplementary Table 4). Intrigued by this discrepancy, we evaluated the relation of these two SNPs to the ratio of TREM1 (a pro-inflammatory receptor¹³) to TREM2 (an anti-inflammatory receptor¹³), since both genes lie in the same locus and the inflammatory potential of a monocyte results from the balance of such competing forces. Interestingly, we found that the AD pathology risk allele rs6910730^G was more strongly associated with a decreased TREM1/TREM2 ratio ($z_{\text{joint}}=-4.47$, $p_{\text{joint}}=7.95\times 10^{-6}$) when compared to the non-AD associated SNP rs2627567 ($z_{\text{joint}}=-2.54$, $p_{\text{joint}}=0.011$) suggesting that the *TREM1* association with AD may be mediated not by a simple reduction of TREM1 expression (in which case rs2627567 would be expected to influence AD pathology) but by influencing the balance of signaling molecules that affect myeloid activation. In an exploratory manner, we looked more carefully at our data and noted that the SNPs' effect on the TREM1/TREM2 ratio was driven by the younger PGP subjects, as it is not seen in the smaller set of older HABS subjects (Supplementary Fig. 3a). Using all PGP subjects from the discovery and replication experiments, the AD pathology risk allele rs6910730^G was associated with an increase in TREM2 ($z_{\text{PGP_meta}}=2.32$, $p_{\text{PGP_meta}}=0.021$; Fig. 1c), while the non-AD associated allele rs2627567^A was associated with a decrease in TREM2 ($z_{\text{PGP_meta}}=-2.43$, $p_{\text{PGP_meta}}=0.015$; Fig. 1d). Thus, in younger PGP individuals, rs6910730^G was more strongly associated with a decreased TREM1/TREM2 ratio ($z_{\text{PGP_meta}}=-5.19$, $p_{\text{PGP_meta}}=2.08\times 10^{-7}$) when compared to the non-AD associated SNP rs2627567^A ($z_{\text{PGP_meta}}=-1.88$, $p_{\text{PGP_meta}}=0.061$) (Supplementary Fig. 3b). These data suggest that while both SNPs affect TREM1 expression, they may have opposite, weaker effects on TREM2 expression leading to differences in the ratio of TREM1 to TREM2 in PGP. We did not see this effect on TREM2 and the TREM1/TREM2 ratio in our smaller set of older HABS subjects, and therefore additional data in both younger and older subjects are needed to further explore the possibility of an age-specific effect of this *TREM1* variant. We also noted that TREM1 expression increased with advancing age in younger subjects ($t_{162}=3.35$, $p_{\text{PGP_meta}}=9.98\times 10^{-4}$) but not in older subjects ($t_{58}=-1.37$, $p_{\text{HABS}}=0.18$), further suggesting that age may affect expression of genes from the *TREM* locus.

In the *CD33* locus, conditioning on rs3865444 uncovered rs3826656^A, which was associated with increased CD33 surface expression ($z_{\text{joint}}=4.91$, $p_{\text{joint}}=9.25\times 10^{-7}$) (Table 1). This *cis*-pQTL, although weaker than rs3865444, was also observed in existing ROS-MAP data ($t_{153}=3.65$, $p=3.60\times 10^{-4}$) and at the mRNA level in existing ImmVar monocyte data ($t_{209}=-2.19$, $p=0.03$)¹². Interestingly, while rs3865444^C and rs3826656^A are both associated with increased CD33 expression, the two SNPs have contrasting associations with AD susceptibility^{6,10,14,15}. It's important to note that rs3865444^C is associated with greater expression of the full-length CD33 isoform¹⁶, whereas the effect of rs3826656 on the different isoforms needs further characterization.

We then turned to our principal goal of identifying AD-associated *trans*-pQTLs. In the discovery phase, four loci displayed suggestive evidence of association *in trans* ($p<0.01$, Supplementary Table 3). We limited the validation effort to these four SNP:protein pairs, of which two validated after Bonferroni correction (Table 1). First, rs2718058^A, an AD

susceptibility allele in the *NME8* locus, was associated with increased *PTK2B* expression ($z_{\text{disc_meta}}=2.73$, $p_{\text{disc_meta}}=6.39\times 10^{-3}$), which was subsequently validated ($(z_{\text{val}}=2.60$, $p_{\text{val}}=9.26\times 10^{-3}$), ($z_{\text{joint}}=3.59$, $p_{\text{joint}}=3.27\times 10^{-4}$)). The direction of effect in relation to AD risk is consistent with that of the *PTK2B cis*-pQTL above, where the risk allele rs28834970^C is also associated with greater *PTK2B*. Second, the primary *CD33* risk allele rs3865444^C was associated with greater *TREM2* surface expression in both the discovery ($z_{\text{disc_meta}}=3.16$, $p_{\text{disc_meta}}=1.6\times 10^{-3}$) and validation phases ($(z_{\text{val}}=2.55$, $p_{\text{val}}=0.011$), ($z_{\text{meta}}=3.99$, $p_{\text{joint}}=6.69\times 10^{-5}$); Table 1 and Fig. 2a). Adjusting for *CD33* surface expression in this model reduced the association of rs3865444 with *TREM2* expression by 80% in PGP and 75% in HABS suggesting that the SNP's relationship to *TREM2* is mediated by the surface expression of *CD33*. Interestingly, the *NME8* and *CD33 trans*-pQTLs were not observed at the mRNA level¹² (although it is possible that the 211 European American subjects of the ImmVar Project were insufficient to detect these associations). This suggests that their effects on *PTK2B* and *TREM2*, respectively, are not mediated by altering transcription, thus highlighting the importance of protein-level characterization in QTL studies. While the validation p-values are modest because of our sample size, the effect of these SNPs on protein expression is tangible: in the validation data, the *NME8* variant explains 15% of the variance in *PTK2B* expression while the *CD33* variant explains 14% of the variance in *TREM2* surface expression.

To further validate and probe the effect of *CD33* on *TREM2* expression, we suppressed *CD33* signaling with an anti-*CD33* antibody in primary monocytes from 24 PGP subjects and observed a decrease in *TREM2* surface expression compared to the isotype control ($t_{23}=-11.0$, $p=1.23\times 10^{-10}$). This result was replicated in an additional 19 subjects ($(t_{18}=-4.66$, $p_{\text{rep}}=1.93\times 10^{-4}$), ($z_{\text{meta}}=-7.29$, $p_{\text{joint}}=3.20\times 10^{-13}$); Fig. 2b and 2c), supporting our pQTL analysis and demonstrating that the protein levels of *CD33* and *TREM2* are linked and that *TREM2* may lie downstream of *CD33*.

Given the positive association of *CD33* expression level with amyloid burden¹⁰ and *TREM2*, we examined the relationship between *TREM2* and AD pathology in ROS-MAP data and found that increased *TREM2* mRNA expression in the dorsolateral prefrontal cortex of ROS-MAP subjects was associated with greater amyloid load ($t_{487}=3.08$, $p=2.23\times 10^{-3}$; Fig. 2d) as well as a pathologic diagnosis of AD ($z=2.58$, $p=9.86\times 10^{-3}$). Conditioning on amyloid burden abolished the association of *TREM2* mRNA with an AD diagnosis ($z=0.38$, $p=0.70$), suggesting that the association of *TREM2* expression with AD may be mediated by accumulation of amyloid pathology, as is the case for *CD33*¹⁰.

Our study measuring *cis*- and *trans*-pQTLs in primary human monocytes begins to map the effects of AD susceptibility variants as they converge at the protein level to alter innate immune function and affect disease susceptibility. To test the robustness of the joint meta-analysis, we also derived empirical p-values by permuting genotypes 10,000 times ($p\hat{=}1.3\times 10^{-3}$ for *NME8*:*PTK2B* and $p\hat{=}9\times 10^{-4}$ for *CD33*:*TREM2*). Even when we account for all 156 SNP:protein combinations tested in the discovery study using a False Discovery Rate approach, we find that *NME8*:*PTK2B* (q-value=0.039) and *CD33*:*TREM2* (q-value=0.033) are likely to be true positive results. Additionally, although our sample size was limited due to practical difficulties in accumulating viable frozen cells from large

numbers of genotyped human subjects, we were still able to detect and validate the reported effects. Larger sample sizes would increase our power to validate additional *cis*-eQTLs at the protein level and to detect more modest SNP:protein associations in our dataset that could not be detected with our current sample size. We illustrate our most interesting findings in Supplementary Fig. 4.

Although the rare *TREM2* R47H mutation is known to confer high risk for AD^{3,17}, *TREM2*'s exact role in the disease is still unclear. Several murine studies suggest a beneficial role for *TREM2* in reactive microgliosis¹⁸, suppressing inflammation^{18,19}, and promoting phagocytosis of amyloid beta and apoptotic neurons^{17,19}. However, a recent study demonstrated that *TREM2* loss-of-function in an AD mouse model reduced brain inflammation and pathology, which was coincident with a significant reduction of monocyte-derived macrophages in the brain²⁰. Consistent with this latter study, our results reporting an association of the *CD33* AD risk allele with increased *TREM2*, as well as higher cortical *TREM2* RNA expression with increasing amyloid pathology, support a pathogenic role for increased *TREM2* expression by peripherally-derived myeloid cells in AD susceptibility. Overall, our results (1) lay the groundwork for future mechanistic studies determining the molecular/signaling mechanisms underlying the *CD33*:*TREM2* and *NME8*:*PTK2B* *trans* associations as well as the functional relevance of these relationships in human macrophages and microglia present at the site of pathology, (2) guide modeling of AD susceptibility networks, (3) identify potential blood-derived biomarkers, and (4) inform the future design of therapeutic strategies (such as those targeting *CD33* and *TREM2*) to modulate the immune system to prevent AD.

Online Methods

Study subjects

Informed consent was obtained from all human subjects. All blood draws, brain autopsies, experiments and data analysis were done in compliance with protocols approved by the Partners Human Research Committee and the Rush University Institutional Review Board.

PhenoGenetic Project (PGP)

Our study takes advantage of data and peripheral blood samples from healthy subjects in the PhenoGenetic Project at Brigham and Women's Hospital. The PGP was launched as a living biobank that provides a source of fresh and frozen biological samples derived from peripheral blood, urine and saliva of genotyped human subjects. 1,753 healthy subjects >18 years old have been recruited from the general population of Boston. The subjects are of diverse ethnicities (29% are non-Caucasian) and are 62.7% women. All subjects used for pQTL analyses were of European ancestry (n=165), as determined from principal components derived from genome-wide genotype data using EIGENSTRAT.

Harvard Aging Brain Study (HABS)

The HABS is a prospective study on cognitively non-impaired older subjects where the overall goal is to determine whether healthy individuals with increases in brain amyloid are in the prodromal stages of AD. For the study, participants, aged 65–90, come in for routine

clinical and neuroimaging phenotyping as well as blood sampling; a detailed description of the study has been previously reported¹⁰. In total, 276 subjects are enrolled in the study and 161 are genotyped. The subjects are of diverse ethnicities (19% are non-Caucasian) and are 59.4% women. All subjects used for pQTL analyses were of European ancestry (n=61), as determined from principal components derived from genome-wide genotype data using EIGENSTRAT.

Religious Orders Study (ROS) and Memory and Aging Project (MAP)

ROS and MAP are prospective studies of aging where study participants are cognitively normal at enrollment, agree to annual clinical evaluations and have signed an Anatomic Gift Act donating their brains at the time of death. Each subject undergoes a detailed quantitative neuropathological examination, detailed ante-mortem clinical and neuropsychological profiling, and banking of peripheral blood mononuclear cells. The follow-up rate of survivors exceeds 90% and the autopsy rate exceeds 80%. A further description of ROS and MAP can be found elsewhere^{21–23}. All subjects used for CD33 surface expression analysis (n=151) and *TREM2* RNA analysis from the dorsolateral prefrontal cortex (n=489) were of European ancestry, as determined from principal components derived from genome-wide genotype data using EIGENSTRAT.

Genotyping

PGP and HABS subjects were genotyped from whole blood DNA using the Illumina Infinium HumanOmniExpressExome BeadChip Kit (San Diego, CA) and the Affymetrix Axiom Biobank Genotyping Array (Santa Clara, CA), respectively. In short, EIGENSTRAT v3.0 was used to identify population outliers, which were discarded. The BEAGLE software (version: 3.3.2) was used to impute the post-QC genotyped markers using reference Haplotype panels from the 1000 Genomes Project Consortium Phase I Integrated Release Version 3 (for PGP) or Version 1 (for HABS). These methods are described in detail elsewhere¹².

In ROS-MAP, DNA was extracted from whole blood or frozen post-mortem brain tissue. Genotype data was generated using the Affymetrix Genechip 6.0 platform at the Broad Institute's Genetic Analysis Platform or the Translational Genomics Research Institute, as previously described²⁴. In short, data underwent quality control analyses using the PLINK toolkit (<http://pngu.mgh.harvard.edu/~purcell/plink/>) and quality controlled genotypes were pooled. The quality control process included a principal components analysis using default parameters in EIGENSTRAT to identify and remove population outliers. Imputation in ROS-MAP was performed using MACH software (version 1.0.16a) and HapMap release 22 CEU (build 36).

Flow Cytometry

For staining, frozen peripheral blood mononuclear cells (PBMCs) from each subject were thawed, washed, counted using the Cellometer Auto 2000 Cell Viability Counter (Nexcelom Bioscience, Lawrence, MA), pre-treated with Fc receptor block (BioLegend, San Diego, CA) and double-stained according to the manufacturer's recommendations in the following combinations: (1) FITC-CD33 antibody (clone AC104.3E3) (Miltenyi Biotec, Auburn, CA)

with either APC-TREM1 antibody (clone TREM-26) (BioLegend), APC-TREM2 antibody (clone 237920) (R&D, Minneapolis, MN (for specificity see <http://www.rndsystems.com/Products/FAB17291A> and Jay *et al.*²⁰)) or PE-TREML2 antibody (MIH61) (BioLegend) and (2) PE-CD33 antibody (clone AC104.3E3) (Miltenyi Biotec) with unconjugated PTK2B antibody (clone 9H12L1) (Life Technologies, Carlsbad, CA) followed by Alexa Fluor 647 goat anti-rabbit secondary antibody (Life Technologies). Cells were also single-stained with unconjugated TYROBP antibody (clone 406288) (R&D) followed by APC goat anti-mouse secondary (R&D). For intracellular staining (PTK2B and TYROBP), PBMCs were permeabilized with 0.1% saponin (Sigma, St. Louis, MO). Following staining with antibodies, cells were subsequently washed, fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) and analyzed within 24 hours. Data was collected on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA) or MACSQuant Analyzer (Miltenyi Biotec) and compensated and analyzed using FlowJo software (TreeStar Inc., Ashland, OR). Staining was performed in batches of 11–12 subjects and monocytes were gated based on forward-side scatter analysis or CD33-positive staining.

RNA-sequencing

RNA was isolated from frozen dorsolateral prefrontal cortex tissue of ROS-MAP subjects using the miRNeasy Mini Kit and RNase-Free DNase Set (Qiagen, Germantown, MD). RNA concentration and quality were determined using a Nanodrop (Thermo Fisher Scientific, Wilmington, DE) and Bioanalyzer (Agilent Technologies, Santa Clara, CA), respectively. Only samples with a RIN score >5 were used for library construction, which was assembled using the strand-specific dUTP method. The library was read using Illumina HiSeq with 101 base pair paired-end reads and a goal coverage of >85 million paired-end reads.

CD33 suppression studies

Monocytes were negatively isolated from PBMCs using the Monocyte Isolation Kit II (Miltenyi Biotec) and plated at 100,000 cells/well in 96-well round-bottom polypropylene plates with RPMI 1640-GlutaMax™ (Life Technologies), containing 10% FBS (Corning), 100 units/ml penicillin (Lonza), 100 µg/ml streptomycin (Lonza), 2.5 µg/ml fungizone (Life Technologies) and either 10 µg/ml LEAF purified anti-CD33 antibody (clone WM53) (BioLegend) or isotype control (BioLegend). Control media without antibody was also used as a negative control. Clone WM53 was chosen because it has been previously shown to suppress CD33 inhibition of inflammatory cytokine secretion²⁵. Monocytes were cultured for 48 hours after which they were washed and stained with Violet LIVE/DEAD Fixable Stain (Life Technologies), FITC-CD33 antibody (clone AC104.3E3) (Miltenyi Biotec) and APC-TREM2 antibody (clone 237920) (R&D). Cells were fixed in 4% paraformaldehyde and analyzed by flow cytometry. Subjects used for these studies were of European (n=22), African American (n=10), East Asian (n=9) and mixed Asian/European ancestry (n=2).

Statistical analysis

In summary, 26 SNPs were selected for the study (see Supplementary Table 2 for the complete list and associated references); these SNPs were (1) previously identified and/or

validated in a meta-analysis of AD GWAS published by Lambert *et al.*, (2) found to have significant association with AD-related phenotypes (meeting genome-wide/Bonferroni significance), or (3) identified to have a significant *cis*-eQTL in monocytes (meeting Bonferroni significance). For the discovery phase, we limited our analysis to the 156 SNP:protein pairs (26 SNPs \times 6 proteins) and created a $p \leq 0.01$ cut-off to identify suggestive *trans*-pQTL results. Four SNP:protein pairs met this threshold and were followed up in the validation phase leaving a Bonferroni significance threshold of $p \leq 0.013$ ($p=0.05/4$) to identify statistically-significant *trans* associations. A threshold of genome-wide significance, while critical in the gene discovery phase conducted by consortia of investigators to identify robust AD susceptibility loci to account for the millions of tested SNPs, is overly conservative and not appropriate in the type of follow-on functional study presented here, in which we take selected, validated susceptibility variants and conduct experiments to understand their functional consequences. Instead, we correct for the number of hypotheses being tested in the study.

Protein expression data was gathered in a series of five experiments, each consisting of 3–6 batches of 7–12 subjects/batch. European subjects were chosen randomly from available samples. The discovery dataset consisted of 176 unique subjects assayed over four experiments. Two of the experiments assayed samples from the PGP cohort ($n=49$, $n=66$) and the other two experiments assayed samples from the HABS cohort ($n=31$, $n=30$). An additional 50 unique subjects from the PGP cohort comprised the validation data set and were assayed in a single experiment. Each experiment was analyzed separately prior to being combined into a meta-analysis. In order to reduce undue influence of outliers and approximate a normal distribution within each experiment, expression levels were rank-based inverse normalized using Equation 1. r_{ijk} is the rank, N_{jk} is the sample size, and Y_{ijk} is the expression level, where i indexes the subject, j indexes the experiment and k indexes the protein.

$$Y_{ijk}^t = \phi^{-1}((r_{ijk} - 3/8)/(N_{jk} - 6/8 + 1)), \quad \text{Equation 1}$$

After normalizing expression data, we performed linear regression for each SNP-protein pair, after first adjusting for batch using an Empirical Bayes priors distribution estimation framework (Combat version 2.0) available in the *sva* R package²⁶. Within this regression, we set expression as the dependent variable and SNP as the independent variable, controlling for possible confounders such as age, sex, and cell viability. The t-statistics of each SNP-protein pair from the linear regressions of the discovery experiments were then meta-analyzed using the weighted-Z method as written in Equation 2, which is commonly used in meta-analysis in the GWAS setting²⁷, to produce discovery stage p-values. The validation experiment was similarly analyzed, producing validation stage p-values for those SNP:protein pairs selected at the end of the discovery analysis. The final joint analysis p-value (discovery plus validation) was the result of a meta-analysis of all five experiments - four discovery and one validation. Additionally, to derive empirical p-values for the joint meta-analysis, we permuted genotypes 10,000 times. Conditional SNP analyses were performed in a similar manner, where the linear regression was also adjusted for the conditional SNP. To calculate the effect of anti-CD33 antibody on TREM2 expression, a

paired *t*-test on raw median fluorescence intensity (MFI) values based on live cell gating was applied to compare isotype and anti-CD33 conditions. To object a joint p-value combining the primary experiment and its replication, the weighted-Z meta-analysis method was used (Equation 2).

In secondary analyses (e.g. analysis of co-expression, regressions conditional on expression, or reported effect estimates) the effects of batch and cell viability were removed from protein levels prior to analysis. To accomplish this, data from all experiments were collapsed into a single data set, expression levels were rank-based inverse normalized, and then adjusted for batch (23 in total) with Combat. Finally, expression levels were regressed against cell viability to produce analysis-ready residuals. For visual representation of the data in Figures 1 and 2 and Supplementary Figure 3, batch adjusted residuals for PGP and HAB were created independently prior to plotting.

In the ROSMAP RNA-seq analysis, expression levels were obtained after applying a series of QC measures. FPKM (Fragments per Kilobase of Exon Per Million Fragments Mapped) were first quantile normalized with Combat correcting for batch. Then, to obtain analysis ready residuals, $\log_2(\text{Combat adjusted FPKM})$ values were then regressed against RIN score, $\log_2(\text{total aligned reads})$, post-mortem interval, age, sex, cohort (ROS/MAP), genotyped PCs, and genotyping platform. Finally, residuals were rank-based inverse normalized. Amyloid and TREM2 were analyzed with linear regression, while pathological AD and TREM2 were analyzed with logistic regression. All analyses were conducted in R (version 3.0.2) and graphed in GraphPad Prism 6. A supplementary methods checklist is available.

$$Z = \frac{\sum_i Z_i w_i}{\sqrt{\sum_i w_i^2}} \quad \text{Equation 2}$$

$$w_i = \sqrt{n_i}$$

$n_i = \text{sample size of experiment } i$

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements


The authors are grateful to the participants of PGP, HABS, ROS and MAP for the time and specimens that they contributed. This work was supported by the US National Institutes of Health grants R01 AG036836, R01 AG048015, R01 AG043617, P01 AG036694, P30 AG10161, R01 AG15819, R01 AG17917, and U01 AG46152.

Glossary

Prot.	Protective
P_{disc}	discovery p-value
P_{val}	validation p-value
P_{joint}	joint p-value (meta-analysis of discovery and validation data)
R²_{val}	proportion of variance in the target protein's expression explained by the selected SNP in the validation data.

References

- Hollingsworth P, et al. *Nat. Genet.* 2011; 43:429–435. [PubMed: 21460840]
- Cruchaga C, et al. *Neuron.* 2013; 78:256–268. [PubMed: 23562540]
- Guerreiro R, et al. *New Engl. J. Med.* 2013; 368:117–127. [PubMed: 23150934]
- Lambert JC, et al. *Nat. Genet.* 2013; 45:1452–1458. [PubMed: 24162737]
- Benitez BA, et al. *Neurobiol. Aging.* 2014; 35:1510.e19–1510.e26. [PubMed: 24439484]
- Naj AC, et al. *Nat. Genet.* 2011; 43:436–441. [PubMed: 21460841]
- Replogle JM, et al. *Ann. Neurol.* 2015; 77:469–477. [PubMed: 25545807]
- Lee CYD, Landreth GE. *J. Neural Transm.* 2010; 117:949–960. [PubMed: 20552234]
- Mildner A, et al. *J. Neurosci.* 2011; 31:11159–11171. [PubMed: 21813677]
- Bradshaw EM, et al. *Nat. Neurosci.* 2013; 16:848–850. [PubMed: 23708142]
- Zhang B, et al. *Cell.* 2013; 153:707–720. [PubMed: 23622250]
- Raj T, et al. *Science.* 2014; 344:519–523. [PubMed: 24786080]
- Klesney-Tait J, Turnbull IR, Colonna M. *Nat. Immunol.* 2006; 7:1266–1273. [PubMed: 17110943]
- Bertram L, et al. *Am. J. Hum. Genet.* 2008; 83:623–632. [PubMed: 18976728]
- Yuan Q, Chu C, Jia J. *Neurol. Sci.* 2012; 33:1021–1028. [PubMed: 22167654]
- Raj T, et al. *Hum. Mol. Genet.* 2014; 23:2729–2736. [PubMed: 24381305]
- Kleinberger G, et al. *Sci. Transl. Med.* 2014; 6:243ra86.
- Wang Y, et al. *Cell.* 2015; 160:1061–1071. [PubMed: 25728668]
- Jiang T, et al. *Neuropsychopharmacology.* 2014; 39:2949–2962. [PubMed: 25047746]
- Jay TR, et al. *J. Exp. Med.* 2015; 212:287–295. [PubMed: 25732305]
- Bennett DA, et al. *Neuroepidemiology.* 2005; 25:163–175. [PubMed: 16103727]
- Bennett DA, et al. *Curr. Alzheimer Res.* 2012; 9:646–663. [PubMed: 22471867]
- Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. *Curr. Alzheimer Res.* 2012; 9:628–645. [PubMed: 22471860]
- De Jager PL, et al. *Neurobiol. Aging.* 2012; 33:1017.e1–1017.e15. [PubMed: 22054870]
- Lajaunias F, Dayer J-M, Chizzolini C. *Eur. J. Immunol.* 2005; 35:243–251. [PubMed: 15597323]
- Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. *Bioinformatics.* 2012; 28:882–883. [PubMed: 22257669]
- Willer CJ, Li Y, Abecasis GR. *Bioinformatics.* 2010; 26:2190–2191. [PubMed: 20616382]




Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





Figure 1. *TREM1* association with AD may not be mediated by a simple reduction of *TREM1* expression but by a balance of *TREM1* and *TREM2*

(a and b) The *TREM1* AD-risk allele rs6910730^G and the non-disease associated *TREM1* allele rs2627567^A are associated with lower *TREM1* expression. (Note: two rs6910730 GG subjects are combined with the AG subjects). (c and d) Stratified analyses limited to the larger collection of PGP subjects (combining the discovery and replication PGP samples): rs6910730^G is associated with an increase in *TREM2* (whereas rs2627567^A is associated with a decrease in *TREM2*), resulting in a greater reduction in the *TREM1*/*TREM2* ratio than that caused by the reduction in *TREM1* expression alone (Supplementary Fig. 3b). *TREM1* and *TREM2* surface expression on monocytes was quantified via flow cytometry; the y-axis represents normalized median fluorescence intensity (MFI) and the horizontal line denotes mean MFI. Each dot represents one individual from either the PGP (●) or HABS (○) cohort.




Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript



TREM2



Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. CD33 modulates TREM2 surface expression

(a) The CD33 risk allele rs3865444^C, which is associated with increased CD33 expression, was also associated with increased TREM2 surface expression on monocytes. TREM2 was quantified via flow cytometry; the y-axis represents normalized MFI and the horizontal line denotes mean MFI. (b) Representative histogram of TREM2 expression on monocytes from one subject; in the presence of the anti-CD33 antibody (Ab), the distribution of TREM2 staining shifts left when compared to monocytes treated with non-specific isotype control Ab. (c) TREM2 MFI of monocytes treated with anti-CD33 Ab decreases compared to

monocytes treated with isotype control Ab. Lines connect paired samples for each individual. **(d)** *TREM2* mRNA expression in dorsolateral prefrontal cortex tissue in relation to amyloid load. The y-axis represents mRNA expression values \log_2 transformed and normalized. Each data point represents one individual.

Table 1

Summary of top pQTL effects^a

SNP	Locus	Protein	Risk/Prot. Allele ↑↓ ^b	P _{disc} ^c	P _{val}	P _{joint} ^d	R ² _{val}
<i>cis</i> -pQTL							
rs3865444	CD33	CD33	C↑/A↓	6.53 × 10 ⁻³³	6.44 × 10 ⁻¹¹	3.12 × 10 ⁻⁴²	0.60
rs3826656 ^e	CD33	CD33	G↑/A↓	7.00 × 10 ⁻⁶	0.045	9.25 × 10 ⁻⁷	0.094
rs2627567 ^f	TREM1	TREM1	A↓/C↑	5.36 × 10 ⁻⁶	0.044	6.89 × 10 ⁻⁷	0.082
rs6910730	TREM1	TREM1	G↓/A↑	2.87 × 10 ⁻³	2.47 × 10 ⁻³	5.02 × 10 ⁻⁵	0.17
rs28834970	PTK2B	PTK2B	C↑/T↓	0.017	5.33 × 10 ⁻³	6.36 × 10 ⁻⁴	0.16
<i>trans</i> -pQTLs							
rs3865444	CD33	TREM2	C↑/A↓	1.60 × 10 ⁻³	0.011	6.69 × 10 ⁻⁵	0.13
rs2718058	NME8	PTK2B	A↑/G↓	6.39 × 10 ⁻³	9.26 × 10 ⁻³	3.27 × 10 ⁻⁴	0.14
rs10498633	SLC24A4/RIN3	TREM2	G↑/T↓	8.18 × 10 ⁻³	----	----	----
rs190982	MEF2C	TREM1	A↑/G↓	7.19 × 10 ⁻³	----	----	----

^a Complete results for the discovery phase can be found in Supplementary Table 3.

^b Arrow indicates direction of effect relative to the indicated allele.

^c Meta-analysis p-value for discovery phase (discovery PGP and HABS subjects combined).

^d Joint p-value combining discovery and validation phases.

^e Conditioned on rs3865444.

^f rs2627567 is not associated with AD (A is the reference allele).

^g Four *trans*-pQTLs met our threshold for attempting validation (p<0.01 in the discovery analysis), and only two were significant in the validation analysis after Bonferroni correction (P<0.013).